NCT05609253View on ClinicalTrials.gov

Itraconazole to Prevent Recurrent Barrett's Esophagus

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 14, 2022

Primary Completion Date

February 23, 2024

Study Completion Date

June 30, 2026

Conditions
Barrett Oesophagitis With Dysplasia
Interventions
DRUG

Itraconazole in capsule form

Patients with high-risk BE will receive two weeks of itraconazole in the capsule form (N=5).

DRUG

Itraconazole in solution form

Patients with high-risk BE will receive two weeks of itraconazole in the solution form (N=5).

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

University of Texas, Southwestern Medical Center at Dallas

OTHER

lead

University of Kansas Medical Center

OTHER